Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day
February 04, 2022 12:06 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming and accelerating drug discovery with...
Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day
January 31, 2022 16:05 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted...
Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences
January 18, 2022 08:00 ET
|
Gain Therapeutics, Inc.
- Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable -- 18th Annual WORLDSymposium –- AD/PD™ 2022 - BETHESDA, Md., Jan. 18, 2022 (GLOBE...
Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference
January 06, 2022 16:05 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have...
Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 28, 2021 16:05 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding...
Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update
December 07, 2021 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding...